Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: A case series

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 5, 2014, Pages 564-566

  Chagas, M H N ^a   Eckeli, A L ^a   Zuardi, A W ^a   Pena Pereira, M A ^a   Sobreira Neto, M A ^a   Sobreira, E T ^a   Camilo, M R ^a   Bergamaschi, M M ^a,b   Schenck, C H ^c   Hallak, J E C ^a,b   Tumas, V ^a   Crippa, J A S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute for Translational Medicine INCT TM CNPq   (Brazil)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

cannabidiol; Parkinson's disease; rapid eye movement sleep behaviour disorder

Indexed keywords

CANNABIDIOL; CANNABIS;

ADULT; AGED; AGITATION; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CASE STUDY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG EFFECT; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARASOMNIA; PARKINSON DISEASE; REM SLEEP; PHYTOTHERAPY; REM SLEEP BEHAVIOR DISORDER;

AGED; CANNABIDIOL; CANNABIS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHYTOTHERAPY; REM SLEEP BEHAVIOR DISORDER;

EID: 84902982268     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12179     Document Type: Article

References (23)

1. Zuardi AW,. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr, 2008; 30: 271-280.
2. Carlini EA, Cunha JM,. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol, 1981; 21: 417S-427S.
3. Schenck CH, Bundlie SR, Mahowald MW,. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology, 1996; 46: 388-393.
4. McCarter SJ, Boswell CL, St Louis EK, et al,. Treatment outcomes in REM sleep behavior disorder. Sleep Med, 2013; 14: 237-242.
5. Boeve BF, Silber MH, Ferman TJ,. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med, 2003; 4: 281-284.
6. Zuardi AW, Crippa JA, Hallak JE, et al,. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol, 2009; 23: 979-983.
7. Chagas MH, Crippa JA, Zuardi AW, et al,. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol, 2013; 27: 312-316.
8. Monti JM,. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology, 1977; 55: 263-265.
9. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R,. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett, 2006; 580: 4337-4345.
10. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R,. The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci, 2008; 122: 1378-1382.
11. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC,. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci, 1991; 11: 563-583.
12. Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O,. Anandamide modulates sleep and memory in rats. Brain Res, 1998; 812: 270-274.
13. Santucci V, Storme JJ, Soubrie P, Le Fur G, Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci, 1996; 58: PL103-PL110.
14. Benarroch EE, Schmeichel AM, Parisi JE,. Depletion of mesopontine cholinergic and sparing of raphe neurons in multiple system atrophy. Neurology, 2002; 59: 944-946.
15. Ringman JM, Simmons JH,. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology, 2000; 55: 870-871.
16. Moldrich G, Wenger T,. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, 2000; 21: 1735-1742.
17. Acquas E, Pisanu A, Marrocu P, Di Chiara G,. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol, 2000; 401: 179-185.
18. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF,. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology, 2010; 75: 494-499.
19. Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J,. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res, 2007; 1134: 162-170.
20. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J,. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis, 2005; 19: 96-107.
21. Price DA, Martinez AA, Seillier A, et al,. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci, 2009; 29: 2177-2186.
22. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA,. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf, 2011; 6: 237-249.
23. Schenck CH, Montplaisir JY, Frauscher B, et al,. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy-a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med, 2013; 14: 795-806.